Celebrating our research achievements
7 April 2017
Researchers and clinicians from Melanoma Institute Australia (MIA) were among the 180 health industry staff, researchers and students whose awards were highlighted at the annual Sydney Medical School’s Celebratory Dinner on 30 March 2017. The evening celebrated the achievements of staff and students from The University of Sydney and its affiliates, like MIA, who have received significant awards during past year.
MIA’s researchers were recognised and celebrated due to their outstanding contributions to health research in Australia.
- Professor John Thompson AO was celebrated for receiving an Honorary Doctorate from Macquarie University and for being named Honorary Fellow of the American College of Surgeons.
- Dr James Wilmott was celebrated for receiving the ‘Wildfire’ Highly Cited Publication Award at the NSW Premier’s Award for Outstanding Cancer Research.
Early lymph node check is saving lives in melanoma patients
We are pleased to announce that A/Prof Anne Cust is the new President of the Australasian Epidemiological Association.
More than $3.5 million in competitive funding grants have been awarded to MIA's researchers.
The ESMO conference provided a platform for announcing a number of key melanoma research findings - including practice-changing research from MIA.
Australian researchers have successfully trialled a combination of new treatments to prevent melanoma from spreading to distant organs.
A new treatment that combines an antibody with a cancer-killing virus improves outcomes for patients with advanced melanoma, an international clinical trial has shown.
It feels like groundhog day - another reality TV show, another batch of blatantly sunburnt contestants.
Wouldn’t it be great if your doctor could know if you would respond to treatment before you even had it?
In our latest research update we showcase research in survival estimates, uncover biomarkers, and reveal practice-changing research in surgery and medical oncology.
Senior Clinical Trial Coordinators, like Sarah Lane, support melanoma patients throughout the clinical trial process.
Melanomas are often hard to differentiate from moles. But new technology is helping to improve accuracy of diagnosis.
We are excited to announce that SunSense will proudly be an official supporter of Melanoma Institute Australia. SunSense is an Australian, family owned business.
Five years ago Julie Randall was diagnosed with melanoma and was given months to live. The melanoma had spread throughout her body. The doctors said it was incurable and she’d be lucky if she survived the next nine months. Julie, a patient at Melanoma Institute Australia under Professor Georgina Long was placed on an experimental drug trial. To watch the entire program, visit 9now.com or click here.
Meet our latest Surgical Oncology Fellow, Eva Nagy, to find out more about life as a surgical oncologist, why she came to MIA and what she hopes to achieve.
Melanoma research at ASCO this year focussed on the more precise use of current treatments to ensure optimal treatment for each patient.
MIA recently demonstrated that reflectance confocal microscopy is a useful tool in the clinic to diagnose suspicious-looking lesions in the mouth.
New research is likely to change the way melanoma is managed in many patients by reducing the need for major surgery and its associated morbidity and cost.
Researchers from MIA will present their latest research findings to the world’s largest oncology conference in early June.